David Siegel

20PUBLICATIONS
98CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Nanotoxicology, health and safetyCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Mar 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Shaji Kumar, Sundar Jagannath, Katja C Weisel

|Feb 17, 2026
Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.

James Di Palma-Grisi, Noa Biran, Pooja Phull

|Jan 21, 2026
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Melissa Alsina, Nina Shah, Sundar Jagannath

|Jun 09, 2025
Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.

Sheri Skerget, Daniel Penaherrera, Ajai Chari

|Aug 19, 2024
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.

Sheri Skerget, Daniel Penaherrera, Ajai Chari

|Aug 17, 2023
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.

Yi Lin, Noopur S Raje, Jesús G Berdeja

Pageof 4

Frequent Collaborators

5 joint publications

Sundar Jagannath

4 joint publications

Jesús G Berdeja

3 joint publications

Daniel Auclair

2 joint publications

Nikhil C Munshi